Curated News
By: NewsRamp Editorial Staff
July 14, 2026

SS Innovations Appoints Sarah Romano as CFO to Drive FDA Approval

Discuss on LinkedIn Discuss on Substack Discuss on Telegram
Original Source

TLDR

  • SSII hires a CFO with capital markets expertise to accelerate FDA approval and global expansion of its SSi Mantra system.
  • Sarah Romano, former CFO of Vicarious Surgical, will lead SSII's financial operations and US regulatory strategy for robotic surgery.
  • SSII aims to make affordable robotic surgery accessible worldwide, improving healthcare equity and patient outcomes.
  • New CFO Sarah Romano raised over $100 million in financing for past companies, signaling strong fundraising capability for SSII.

Impact - Why it Matters

This appointment is crucial as SS Innovations seeks FDA approval for its SSi Mantra system, which could lower the cost of robotic surgery and make it more accessible globally. Romano's proven track record in medtech finance and capital raising positions the company to accelerate its expansion, potentially disrupting the surgical robotics market and improving patient outcomes by offering a more affordable alternative to current systems.

Summary

SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, has appointed Sarah M. Romano as chief financial officer, effective Aug. 3, 2026. Romano brings over two decades of finance leadership in medical technology and life sciences, and will spearhead the company's financial operations as it pursues U.S. FDA approval for its SSi Mantra surgical robotic system and expands globally. Her experience includes serving as CFO at Vicarious Surgical, where she reduced cash burn and strengthened the balance sheet, and raising over $100 million through public and private financings at Entero Therapeutics and Kiora Pharmaceuticals. This strategic hire signals SS Innovations' commitment to scaling its cost-effective robotic surgery solutions to a broader global population.

SS Innovations International (NASDAQ: SSII) is an American company headquartered in India, dedicated to making robotic surgery affordable and accessible. Its product range includes the proprietary "SSi Mantra" surgical robotic system and the "SSi Mudra" suite of surgical instruments, supporting various procedures including cardiac surgery. The company aims to expand the global presence of its user-friendly solutions. To view the full press release, visit https://ibn.fm/pAqlP. For the latest news and updates relating to SSII, check the company’s newsroom at https://ibn.fm/SSII.

This announcement was distributed by MissionIR, a specialized communications platform focused on assisting IR firms with syndicated content to enhance visibility for companies within the investment community. MissionIR is part of the Dynamic Brand Portfolio @ IBN, delivering access to a network of wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. By cutting through information overload, MissionIR provides clients with unparalleled recognition and brand awareness. For more information, visit www.MissionIR.com. Please see full terms of use and disclaimers at https://www.MissionIR.com/Disclaimer. MissionIR is powered by IBN.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, SS Innovations Appoints Sarah Romano as CFO to Drive FDA Approval

blockchain registration record for this content.